UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Muscle & nerve, 2001-08, Vol.24 (8), p.1050-1057

2001

Volltextzugriff (PDF)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

International journal of cancer, 2016-10, Vol.139 (7), p.1648-1657

2016

Volltextzugriff (PDF)

1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1191

2022

Volltextzugriff (PDF)

642 Organic anion transporting polypeptides contribute to prostate cancer progression

European journal of cancer supplements, 2010, Vol.8 (7), p.201-201

2010

Volltextzugriff (PDF)

1206O Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling

Annals of oncology, 2023-10, Vol.34, p.S711-S711

2023

Volltextzugriff (PDF)

605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide

Annals of oncology, 2021-09, Vol.32, p.S647-S647

2021

Volltextzugriff (PDF)

The CYP2C1917 variant is not independently associated with clopidogrel response

Journal of thrombosis and haemostasis, 2013-09, Vol.11 (9), p.1640-1646

2013

Volltextzugriff (PDF)

Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer

Annals of oncology, 2017-09, Vol.28, p.v285-v286

2017

Volltextzugriff (PDF)

A first step in the long road to bring new agents to hepatic artery infusion

HPB (Oxford, England), 2024, Vol.26, p.S665-S666

2024

Volltextzugriff (PDF)

643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

Annals of oncology, 2020-09, Vol.31, p.S527-S528

2020

Volltextzugriff (PDF)

Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

Annals of oncology, 2018-10, Vol.29, p.viii297-viii297

2018

Volltextzugriff (PDF)

OA11.05 Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S127-S128

2021

Volltextzugriff (PDF)

Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

TheScientificWorld, 2014-01, Vol.2014 (2014), p.1-16

2014

Volltextzugriff (PDF)

77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

ESMO open, 2024-10, Vol.9, p.103818, Article 103818

2024

Volltextzugriff (PDF)

A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers

Annals of oncology, 2017-09, Vol.28, p.v130-v130

2017

Volltextzugriff (PDF)

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

BioTechniques, 2002-09, Vol.33 (3), p.664-670

2002

Volltextzugriff (PDF)

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

The pharmacogenomics journal, 2010-06, Vol.10 (3), p.191-199

2010

Volltextzugriff (PDF)

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Clinical lung cancer, 2007-07, Vol.8 (7), p.453-453

2007

Volltextzugriff (PDF)

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

BioTechniques, 2002-09, Vol.33 (3), p.664-670

2002

Volltextzugriff (PDF)

SLCO transport genes in prostate cancer--letter

Cancer epidemiology, biomarkers & prevention, 2011-10, Vol.20 (10), p.2325; author reply 2326-2325

2011

Volltextzugriff (PDF)

Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)

Biology of blood and marrow transplantation, 2012, Vol.18 (2), p.S208-S208

2012

Volltextzugriff (PDF)

Thalidomide, an antiangiogenic agent with clinical activity in cancer

Biomedicine & Pharmacotherapy, 2002-06, Vol.56 (4), p.194-199

2002

Volltextzugriff (PDF)

398 Development of an LC/MS/MS method for the quantitative determination of the Akt inhibitor PIA5 in mouse plasma

European journal of cancer supplements, 2004-09, Vol.2 (8), p.119-119

2004

Volltextzugriff (PDF)

Effect of Prednisone on Prostate-Specific Antigen in Patients With Hormone-Refractory Prostate Cancer

The Journal of urology, 1999, Vol.161 (1), p.360-360

1999

Volltextzugriff (PDF)

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

Annals of oncology, 1996-11, Vol.7 (9), p.939-944

1996

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Science & Technology
(9)
Life Sciences & Biomedicine
(8)
Male
(7)
Biological And Medical Sciences
(6)
Middle Aged
(6)
Adult
(5)
Medical Sciences
(5)
Aged
(4)
Animals
(4)
Oncology
(4)
Pharmacology. Drug Treatments
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer
(3)
Hematology, Oncology And Palliative Medicine
(3)
Neoplasms - Drug Therapy
(3)
Prostatic Neoplasms - Drug Therapy
(3)
Thalidomide
(3)
Toxicity
(3)
Angiogenesis Inhibitors - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)

642 Organic anion transporting polypeptides contribute to prostate cancer progression

1206O Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling

605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide

The CYP2C1917 variant is not independently associated with clopidogrel response

Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer

A first step in the long road to bring new agents to hepatic artery infusion

643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

OA11.05 Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer

Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Microarray Gene Expression Profiling of Angiogenesis Inhibitors Using the Rat Aortic Ring Assay

SLCO transport genes in prostate cancer--letter

Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)

Thalidomide, an antiangiogenic agent with clinical activity in cancer

398 Development of an LC/MS/MS method for the quantitative determination of the Akt inhibitor PIA5 in mouse plasma

Effect of Prednisone on Prostate-Specific Antigen in Patients With Hormone-Refractory Prostate Cancer

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

Suchergebnisse filtern